For the past three years, healthcare artificial intelligence enjoyed a rare operational window: health systems funded software out of discretionary innovation budgets. Chief information officers and clinical department chairs signed enterprise agreements with ambient scribe platforms, automated revenue cycle tools, and computer vision suites. The core pitch focused on burning down physician burnout, accelerating billing capture, and automating back-office friction.

That experimental phase has largely ended. With average hospital operating margins hovering between 1.5% and 3.5%, health system chief financial officers are conducting line-item audits of enterprise software contracts. When annual renewals come up, executive committees are no longer asking whether clinicians like the technology. They are asking: What form of economic return did this software actually deliver, and can that return be proven on our balance sheet?

In this deep dive, we are going to look at:

  • Why this matters now
  • The four distinct definitions of healthcare AI ROI
  • The HealthTech Signal AI ROI Maturity Map across nine categories
  • The evidence ladder: Hard cash displacement versus unproven attribution
  • The administrative layer: Why coding and revenue cycle prove value fastest
  • The ambient documentation paradox: Mixed productivity evidence versus strong workforce utility
  • The prior authorization friction: Payer-provider bottlenecks ahead of CMS-0057-F
  • The unproven categories: Why autonomous agents and clinical decision support stall in procurement
  • The global picture: How international health system structures alter economic payback
  • The HealthTech Investor's Signal: Capital allocation, multiple rationalization, and platform bundling
  • Four concrete milestones to watch over the next 12 to 24 months
  • The bottom line for health system leaders and technology investors